Skip to content
Finance — investing — Vegas Nights: Your Guide to Sin City's Hottest Spots

Pharmaceutical company Mural Oncology agrees to acquire XOMA Royalty Corporation, known as XRA 5 Corp.

Mural Oncology plc has received guidance on their latest deal with XRA 5 Corp, an entirely owned subsidiary of XOMA Royalty.

,   and  Administrator
2 min read
Oncology company Mural PLC agrees to acquire XOMA Royalty Corporation, also known as XRA 5 Corp.
Oncology company Mural PLC agrees to acquire XOMA Royalty Corporation, also known as XRA 5 Corp.

Pharmaceutical company Mural Oncology agrees to acquire XOMA Royalty Corporation, known as XRA 5 Corp.

Mural Oncology plc, a leading biopharmaceutical company, has entered into an agreement with XRA 5 Corp, a wholly owned subsidiary of XOMA Royalty Corporation, for a potential acquisition. According to a press release available on Global News Wire, the legal team advising Mural Oncology plc on this agreement is led by Chris McLaughlin, who is responsible for the Corporate and M&A aspect.

The acquisition consideration structure for this public takeover in Ireland is reportedly unique and a first of its kind. The proposed acquisition value for Mural Oncology plc shares ranges from $2.035 to $2.24 in cash.

The legal team also includes David Vos, Fintan Clancy, Patrick Horan, John Donald, James Cotter, Andrea Bowdren, Susan O'Leary, Zara Murphy, Niamh McCarthy, Jessica Lewis, Nicola Cavey, LĂ­s O'Connor, and Kenneth Dixon. While their specific roles are not detailed in the press release, each member brings their expertise to the table.

Fintan Clancy is responsible for the Tax aspect of the legal team, and Patrick Horan is responsible for the Competition and Regulated Markets aspect, as previously mentioned. John Donald is responsible for the Restructuring and Insolvency aspect.

The roles of James Cotter, Andrea Bowdren, Susan O'Leary, Zara Murphy, Niamh McCarthy, Jessica Lewis, Nicola Cavey, LĂ­s O'Connor, and Kenneth Dixon within the legal team are not specified in the press release. However, their participation is notable, and their contribution to the deal is expected to be significant.

The law firm that advised Mural Oncology plc in this agreement and whose participation was notable due to an unprecedented acquisition consideration structure for a public company in Ireland is ByrneWallace LLP. The firm's involvement underscores the complexity and uniqueness of the deal.

As the deal progresses, more details are expected to be revealed, shedding light on the specifics of this groundbreaking acquisition. Stay tuned for further updates.

Read also:

Related

Latest